



## Results

The CyAn ADP LX 9 Color was set up in three steps:

1. Adjustment of PMT voltages using unstained sample.
2. Acquisition of stained SCC saving 25,000 total events.
3. Setting compensation using Auto Compensation function in Summit software version 4.3 and SCC gated on live lymphocytes.

After setting up the CyAn ADP LX 9 Color, 100,000 total events of the FMO controls were acquired to validate compensation and to correctly set gates (Figure 1).

Ten million events from the analysis sample (stained with HLA-A1 pp50<sub>245-253</sub>/PE multimers), mismatch control (HLA-B8 IE-1<sub>88-96</sub>/PE multimer) and “no multimer” were acquired. High-speed mode of 70,000 events per second for 2:20 minutes was used for all samples.

A total of 1,459 HLA-A1-restricted pp50<sub>245-253</sub>-specific T cells were found in the acquired 10 million events, equivalent to 0.01% (frequency of rare events 1/10,000) of the analyzed cells (Figure 2).

## Gating Strategy

Figure 1





Figure 2



## TECHNICAL TIPS

- It is important to use SSC and FMO controls to correctly set up the instrument and compensation prior to run the sample of interest.
- It is very important that the sample line be cleaned adequately prior to running the samples of interest: Start “sample clean” and run “Decontamination solution,” then “Cleaning and Rinse Solution” and then “DI water.”

## Discussion

Antigen-specific T cells are crucial for protection against intracellular pathogens such as viruses and intracellular bacteria. Loss of antigen-specific T cells or their functional impairment, as observed in immunocompromised patients, can result in severe health conditions.

The herpes virus CMV is found universally throughout all geographic locations and socioeconomic groups, and chronically infects between 50% and 85% of all individuals. Primary CMV infection can become life-threatening for immunocompromised patients. However, the more common clinical problem is the reactivation of latent virus in patients during a longer phase of immuno-suppression, where CMV-related diseases contribute to a large number of severe clinical complications.

The detection and measurement of antigen-specific T cells against CMV has gained specific importance for several fields in clinical research (including organ transplantation, hemodialysis, cancer therapy, immunosup-

pressive treatment, or HIV-infection), since these data might provide important information for further therapeutic decisions.

The big challenge in rare event analysis is discriminating between background and truly positive cells. It is, therefore, indispensable to use specific controls for protocols without amplification. For instrument setup and definition of the gating strategies, unstained cells or stained isotypes are improper controls in multi-color experiments, especially while detecting very small subpopulations. Currently the best controls are stained cells with all reagents except the one of interest (FMO). FMO controls should be used whenever accurate discrimination is essential or when antigen expression is relatively low.

With the software options of Summit software version 4.3 to acquire large number of events and Auto Compensation to easily define compensation, it is now possible to determine *ex vivo* the size of rare populations of antigen-specific T cells with high statistic significance and speed.

## Contributors

Dr. Matthias Schiemann and Dr. Dirk H. Busch, Institute for Microbiology, Immunology and Hygiene, Technical University Munich, Trogerstr. 30, 81675 Munich, Germany.

## Acknowledgements

Special thanks to Katleen Goetsch for the excellent technical assistance.

## References

1. Hataye, J., J.J. Moon, A. Khoruts, C. Reilly, and M.K. Jenkins. 2006. Naive and memory CD4+ T cell survival controlled by clonal abundance. *Science* 312:114-116.

<b>PRODUCT</b>	<b>CODE</b>
CyAn ADP LX 9 Color.....	CY201
Sheath Fluid .....	S2322
SpectrAlign Beads.....	K0111
8-Peak-Beads .....	K0112
Cleaning and Rinse Solution.....	S2323
Decontaminating Solution .....	S2324
CD62L/FITC .....	F7085
CD3/CY .....	CA696
CD8/PE .....	R0806

For research use only – not to be used in diagnostic procedures. Other vendor products used in this application: Invitrogen, Treestar, and BD Bioscience.

The protocols in this application note might deviate from the normal recommended protocol/specification guidelines that are included with the Dako product or any other non-Dako product.



Corporate Headquarters  
Denmark  
+45 44 85 95 00

[www.dako.com](http://www.dako.com)

Distributors in more  
than 50 countries

Australia  
+61 2 9316 4633

Austria  
+43 1 408 4334 50

Belgium  
+32 016 38 72 20

Canada  
+1 905 858 8510

Czech Republic  
+420 541 42 37 10

Denmark  
+45 44 85 97 56

France  
+33 1 30 50 00 50

Germany  
+49 40 69 69 470

Ireland  
+353 91 768150

Italy  
+39 02 58 078 1

Japan  
+81 75 211 3655

The Netherlands  
+31 20 42 11 100

Norway  
+47 23 14 05 40

Poland  
+48 58-661 1879

Spain  
+34 93 499 05 06

Sweden  
+46 08 556 20 600

Switzerland  
+41 41 760 11 66

United Kingdom  
+44 (0)1 353 66 99 11

United States of America  
+1 805 566 6655